From: Non-coding RNAs: a key to future personalized molecular therapy?
miRNA | Disease state | Biological target | In vivomodel | Delivery system | References |
---|---|---|---|---|---|
miR-100 | Nasopharyngeal cancer | Plk1 | 6- to 8-week-old SCID BALB/c female mice | siRNA and ionizing radiation and potential miRNAs that might regulate Plk1 expression | [88] |
Synthetic miR-16 | Metastatic prostate cancer | CDK1 and CDK2 | Bone metastasis mode mice | Injected into tail veins | [89] |
miR-155 | Myeloproliferative disorder | SHIP1 | Mice, specific knockdown of SHIP1 in the hematopoietic system | Retroviral delivery of a miR-155-formatted siRNA against SHIP1 | [90] |
SNORD116 (PWCR1/HBII-85) | Prader-Willi syndrome | Bioinformatic screen located 23 possible targets | C57BL/6 mice | Snord116del mice | [21] |
miR-147 | Inflammation | Cytokine expression in macrophages stimulated with ligands to Toll-like receptors: TLR2, TLR3, TLR4 | LPS-stimulated mouse | Peritoneal macrophages were transfected with 40 nM control miRNA mimics or mouse miR-147 mimics | [91] |
LNA-antimiR-122 | Hypercholesterolemia | miR-122 liver specific | Normal and hypercholesterolemic mice; normal African green monkeys | Intravenous injections unconjugated | [62] |
LNA-antimiR-21 | Glioma | miR-21 | Athymic nude mice | Intracranial cell implantation | [92] |
miR-34a | Normal | E2F family | Nude mice | Subcutaneous administration of miR-34a/collagen complexes | [93] |
mir-17-92 cluster | Normal | c-Myc | Mice reconstituted with hematopoietic stem cells expressing mir-17-19b | Perfusion cells treated by retroviral vector | [94] |